Virus infections allow for tumor-directed DC vaccination in a mouse model of endogenously induced transgenic liver tumors

Tumor-responsive cytotoxic T-cells have great potential for curative tumor therapy. However, DC-vaccines for expansion of antitumoral T-cell responses have so far yielded limited therapeutic success in the treatment of solid cancers. For therapeutic success, breaking tumor-specific tolerance mechanisms appears mandatory before a potent tumor-specific cytotoxic T-cell response can be triggered by immunotherapeutic interventions. In our study we identified tumor-tissue inflammation, induced by intratumoral infection with a telomerase-dependent, tumor-selectively replicating adenovirus, as an important precondition…